Science

Disseminated, metastatic tumors are frequently resistant to existing therapies

K-Lab Therapeutics introduces a highly efficient concept by developing a novel approach to overcoming resistance to cancer immunotherapy by targeting both tumor cells and myeloid-derived suppressor cells (MDSC). This concept has been confirmed by preclinical studies for the treatment of advanced and metastatic cancers

As a novel and effective cancer treatment, our therapeutics elicit a coordinated, robust anti-tumor response by depleting immunosuppressive myeloid cells, remodeling the tumor microenvironment, and recruiting other immune cells that stimulate a powerful T cell-dependent adaptive immune response.

Figure shown below: left panel (A) – lung metastases before treatment; right panel (B) – metastatic clearance in lungs after treatment.